Global Genotyping Market, By Product and Service (Instruments, Reagents and Kits, Bioinformatics, Genotyping Services), Technology (Microarrays, Capillary Electrophoresis, Sequencing, Polymerase Chain Reaction (PCR), Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry, Others Technologies), Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Animal Genetics, Agricultural Biotechnology, Others), End User (Pharmaceutical and Biopharmaceutical Companies, Diagnostic and Research Laboratories, Academic Institutes, Other) – Industry Trends and Forecast to 2030.
Genotyping Market Analysis and Size
The use of genotyping in drug development across the globe is one of the major factors driving the growth of the genotyping market. The increasing prevalence of target diseases, such as cancer, diabetes, and Alzheimer’s, and the introduction of novel technologies for minimizing errors considerably and yielding efficient results accelerate the market growth. The use of the technique for rapid sequencing, the early diagnosis of these diseases above, and the increase in demand among healthcare professionals to decide on probable treatment options further influence the market. Additionally, the rise in the geriatric population, surge in healthcare expenditure, and increase in investments, funds, and grants positively affects the genotyping market. Furthermore, developing advanced products to cater to the increasing demands of the target population extends profitable opportunities to the market players in the forecast period.
Data Bridge Market Research analyses that the genotyping market, which was USD 15,090.25 million in 2022, will reach USD 23,687.45 million by 2030, and is expected to grow at a CAGR of 14.59% during the forecast period of 2023 to 2030. Instruments” dominates the product and service segment of the Genotyping Market owing to the high demand for these types of products. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Genotyping Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2014-2019) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
By Product and Service (Instruments, Reagents and Kits, Bioinformatics, Genotyping Services), Technology (Microarrays, Capillary Electrophoresis, Sequencing, Polymerase Chain Reaction (PCR), Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry, Others Technologies), Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Animal Genetics, Agricultural Biotechnology, Others), End User (Pharmaceutical and Biopharmaceutical Companies, Diagnostic and Research Laboratories, Academic Institutes, Other) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. |
|
Market Players Covered |
Illumina, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Qiagen N.V. (Germany), Fluidigm Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Oxford Nanopore Technologies, Ltd. (U.K.), Pacific Biosciences of California, Inc. (U.S.)., Genewiz, Inc. (U..S.), Genomic Health, Inc. (U.S.), Eurofins Scientific SE (Germany), BGI Group (China), Danaher Corporation (U.S.), Luminex Corporation (U.S.) |
|
Market Opportunities |
|
Market Definition
Genotyping is a technique in which one can analyze genetic make-up differences through biological assays by examining the individual’s DNA sequence. This technique assists the researchers in exploring genetic deviations such as large structural changes in DNA and single nucleotide polymorphisms. Genotyping is the process of determining the DNA sequence, called a genotype, at positions within an individual's genome. Sequence variations can be used as linkage and association studies markers to determine genes relevant to specific traits.
Genotyping Market Dynamics
Drivers
- The increase in the prevalence of target diseases, such as cancer, diabetes, and Alzheimer’s
Growing prevalence of various target diseases such as cancer, diabetes is amongst the essential factors intensifying the growth and demand of genotyping market. As genotyping is majorly used drug development for genetic disorders and rare diseases, this has carved the way for market growth.
- Research and development proficiencies
Rising expenditure for research and development proficiencies, especially in the developed and developing economies about medical drugs and devices will further create lucrative market growth opportunities. Research and development proficiencies being conducted to develop the medical drugs also bolstered the market growth rate.
- Growing investment in healthcare facilities
Surging focus towards improving healthcare facilities' condition and overall healthcare infrastructure is another important factor fostering market growth. The rising number of partnerships and strategic collaborations between the public and private players about funding and application of new and improved Technology is further creating lucrative market opportunities.
Opportunities
- Upsurge in the public-private funding for target research activities
The research activities in the genotyping market has increased globally, which is expected to act as an opportunity for the growth of the market. Hence, the upsurge in public-private funding for research activities is expected to act as an opportunity for the market.
-
Rising product innovations and development owing to technological advancements all around the world
Various companies are launching new and innovative products focused in the genotyping market owing to the different technological advancements, which is further creating an opportunity for the market.
Restraints/Challenges
- Unfavourable reimbursement policies
The stringent rules and regulations and unfavourable reimbursement policies affect the overall market growth, which is one of the restraining factors for the overall market in the forecasted year.
- High cost associated with the research and development proficiencies,
For the development of various products and new advanced technologies, there is a high cost for the setups and to conduct various associated research, which is further projected to impede the dry skin treatment market growth in the timeline period.
This genotyping market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the genotyping market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
Recent Development
- In 2021, Thermo Fisher Scientific launched the Ion Torrent Genexus System, which is designed to enable rapid and accurate genotyping in clinical settings. This has helped company to increase their global presence in the market
- In 2020, Illumina launched several new genotyping products, including the Infinium Global Diversity Array, which includes over 1.7 million markers to enable population-scale genotyping. This has helped company to increase their overall revenue for the company
Global Genotyping Market Scope
The genotyping market is segmented based on product and services, Technology, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product and Services
- Instruments
- Reagents and Kits
- Bioinformatics
- Genotyping Services
Technology
- Microarrays
- Capillary Electrophoresis
- Sequencing
- Polymerase Chain Reaction (PCR)
- Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof)
- Mass Spectrometry
- Others Technologies
Application
- Pharmacogenomics
- Diagnostics and Personalized Medicine
- Animal Genetics
- Agricultural Biotechnology
- Others
End Users
- Pharmaceutical and Biopharmaceutical Companies
- Diagnostic and Research Laboratories
- Academic Institutes
- Other
Genotyping Market Regional Analysis/Insights
The genotyping market is analyzed and market size insights and trends are provided by country, product and services, Technology, application, and end-user, as referenced above.
The countries covered in the genotyping market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the genotyping market because of the strong base of healthcare facilities, strong presence of major players in the market, and the rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in healthcare facilities, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Genotyping Market Share Analysis
The genotyping market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the genotyping market.
Some of the major players operating in the genotyping market are:
- Illumina, Inc. (U.S.)
- F. Hoffmann-La Roche AG (Switzerland)
- Thermo Fisher Scientific, Inc. (U.S.)
- Qiagen N.V. (Germany)
- Fluidigm Corporation (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Oxford Nanopore Technologies, Ltd. (U.K.)
- Pacific Biosciences of California, Inc. (U.S.)
- Genewiz, Inc. (U.S.)
- Genomic Health, Inc. (U.S.)
- Eurofins Scientific SE (Germany)
- BGI Group (China)
- Danaher Corporation (U.S.)
- Luminex Corporation (U.S.)
SKU-
